Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
2'-5' oligoadenylate synthetase-like 1 (OASL1) deficiency suppresses central nervous system damage in a murine MOG-induced multiple sclerosis model.
Neuromuscular Electrical Stimulation Can Improve Walking Endurance In Individuals With Multiple Sclerosis: 2573 Board #96 June 3, 9: 30 AM - 11: 00 AM.
[Progressive multifocal leukoencephalopathy].
Regional differences in interhemispheric structural fibers in healthy, term infants.
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.
The association between IgG and IgM antibodies against cardiolipin, β2-glycoprotein I and Domain I of β2-glycoprotein I with disease profile in patients with multiple sclerosis.
Exploring the feasibility and acceptability of sensor monitoring of gait and falls in the homes of persons with multiple sclerosis.
Role of Sonic Hedgehog Signaling in Oligodendrocyte Differentiation.
Fingolimod enhances myelin repair of hippocampus in pentylenetetrazol-induced kindling model.
Thickening of the peripheral nerves in metachromatic leukodystrophy.
Neuromyelitis optica and tactile and visual hallucinations in an elderly patient.
Brain activation changes during locomotion in middle-aged to older adults with multiple sclerosis.
MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.
Structural determinant for inducing RORgamma specific inverse agonism triggered by a synthetic benzoxazinone ligand.
Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk.
Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis.
Combined effects of transferrin and thyroid hormone during oligodendrogenesis In vitro.
Severe articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosis.
Erratum to: 'Purkinje cell injury, structural plasticity and fusion in patients with Friedreich's ataxia'.
Design, synthesis and docking studies of novel 1,2-dihydro-4-hydroxy-2-oxoquinoline-3-carboxamide derivatives as a potential anti-proliferative agents.
Aging-Resilient Associations between the Arcuate Fasciculus and Vocabulary Knowledge: Microstructure or Morphology?
Acute Disseminated Encephalomyelitis.
Pharmaceutical Approval Update.
Targeting "bad" B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
Pages
« first
‹ previous
…
779
780
781
782
783
784
785
786
787
…
next ›
last »